TC
EW icon

Truvestments Capital’s Edwards Lifesciences EW Stock Holding History

Truvestments Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.4K Sell
900
-176
-16% -$14.7K 0.01% 442
2026
Q1 		$86.2K Hold
1,076
– – 0.02% 405
2025
Q4 		$91.7K Hold
1,076
– – 0.02% 352
2025
Q3 		$83.7K Sell
1,076
-572
-35% -$44.7K 0.02% 369
2025
Q2 		$129K Sell
1,648
-60
-4% -$4.47K 0.03% 270
2025
Q1 		$124K Buy
1,708
+60
+4% +$4.29K 0.03% 276
2024
Q4 		$122K Hold
1,648
– – 0.03% 267
2024
Q3 		$109K Buy
+1,648
New +$120K 0.03% 269
2024
Q2 		– Sell
-75
Closed -$7.17K – 384
2024
Q1 		$7.17K Sell
75
-195
-72% -$16.4K ﹤0.01% 522
2023
Q4 		$20.6K Hold
270
– – 0.01% 435
2023
Q3 		$18.7K Hold
270
– – 0.01% 387
2023
Q2 		$25.5K Buy
270
+195
+260% +$16.9K 0.01% 356
2023
Q1 		$6.21K Buy
+75
New +$5.89K ﹤0.01% 484
2019
Q2 		– Sell
-210
Closed -$13K – 734
2019
Q1 		$13K Buy
+210
New +$12K 0.01% 472

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Truvestments Capital's EW Position: Q2 2026 in Review

Truvestments Capital reduced its Edwards Lifesciences (EW) stake by 16% in Q2 2026, selling an estimated $14.7K and leaving 900 shares worth $81.4K. The position accounts for 0.01% of the portfolio, ranked #442.

Truvestments Capital first reported a position in EW in Q1 2019 and has held it in 14 quarters since. The position peaked at $129K in Q2 2025. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Truvestments Capital held 900 shares of Edwards Lifesciences worth $81.4K as of Q2 2026.
  • Truvestments Capital sold 176 Edwards Lifesciences shares in Q2 2026, an estimated $14.7K.
  • Edwards Lifesciences made up 0.01% of Truvestments Capital's portfolio in Q2 2026, its #442 holding.
  • Truvestments Capital first reported a position in Edwards Lifesciences in Q1 2019 and has held it in 14 quarters since.
  • Truvestments Capital's Edwards Lifesciences position peaked at $129K in Q2 2025.
  • 1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.